Flavonoid apigenin is an inhibitor of the NAD+ase CD38: Implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome (Diabetes (2013) 62 (1084-1093))

Carlos Escande; Veronica Nin; Nathan L. Price; Verena Capellini; Ana P. Gomes; Maria Thereza Barbosa; Luke O'Neil; Thomas A. White; David A. Sinclair; Eduardo N. Chini

doi:10.2337/db14-er04

Flavonoid apigenin is an inhibitor of the NAD⁺ase CD38: Implications for cellular NAD⁺ metabolism, protein acetylation, and treatment of metabolic syndrome (Diabetes (2013) 62 (1084-1093))

Carlos Escande, Veronica Nin, Nathan L. Price, Verena Capellini, Ana P. Gomes, Maria Thereza Barbosa, Luke O'Neil, Thomas A. White, David A. Sinclair, Eduardo N. Chini

Anesthesiology

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	1428
Number of pages	1
Journal	Diabetes
Volume	63
Issue number	4
DOIs	https://doi.org/10.2337/db14-er04
State	Published - Apr 2014

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism

Access to Document

10.2337/db14-er04

Cite this

Escande, C., Nin, V., Price, N. L., Capellini, V., Gomes, A. P., Barbosa, M. T., O'Neil, L., White, T. A., Sinclair, D. A., & Chini, E. N. (2014). Flavonoid apigenin is an inhibitor of the NAD⁺ase CD38: Implications for cellular NAD⁺ metabolism, protein acetylation, and treatment of metabolic syndrome (Diabetes (2013) 62 (1084-1093)). Diabetes, 63(4), 1428. https://doi.org/10.2337/db14-er04

Flavonoid apigenin is an inhibitor of the NAD⁺ase CD38: Implications for cellular NAD⁺ metabolism, protein acetylation, and treatment of metabolic syndrome (Diabetes (2013) 62 (1084-1093)). / Escande, Carlos; Nin, Veronica; Price, Nathan L. et al.
In: Diabetes, Vol. 63, No. 4, 04.2014, p. 1428.

Research output: Contribution to journal › Comment/debate › peer-review

Escande, C, Nin, V, Price, NL, Capellini, V, Gomes, AP, Barbosa, MT, O'Neil, L, White, TA, Sinclair, DA & Chini, EN 2014, 'Flavonoid apigenin is an inhibitor of the NAD⁺ase CD38: Implications for cellular NAD⁺ metabolism, protein acetylation, and treatment of metabolic syndrome (Diabetes (2013) 62 (1084-1093))', Diabetes, vol. 63, no. 4, pp. 1428. https://doi.org/10.2337/db14-er04

@article{cd383a8fcb614b298fe7b851eab70a03,

title = "Flavonoid apigenin is an inhibitor of the NAD+ase CD38: Implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome (Diabetes (2013) 62 (1084-1093))",

author = "Carlos Escande and Veronica Nin and Price, {Nathan L.} and Verena Capellini and Gomes, {Ana P.} and Barbosa, {Maria Thereza} and Luke O'Neil and White, {Thomas A.} and Sinclair, {David A.} and Chini, {Eduardo N.}",

year = "2014",

month = apr,

doi = "10.2337/db14-er04",

language = "English (US)",

volume = "63",

pages = "1428",

journal = "Diabetes",

issn = "0012-1797",

publisher = "American Diabetes Association Inc.",

number = "4",

}

TY - JOUR

T1 - Flavonoid apigenin is an inhibitor of the NAD+ase CD38

T2 - Implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome (Diabetes (2013) 62 (1084-1093))

AU - Escande, Carlos

AU - Nin, Veronica

AU - Price, Nathan L.

AU - Capellini, Verena

AU - Gomes, Ana P.

AU - Barbosa, Maria Thereza

AU - O'Neil, Luke

AU - White, Thomas A.

AU - Sinclair, David A.

AU - Chini, Eduardo N.

PY - 2014/4

Y1 - 2014/4

UR - http://www.scopus.com/inward/record.url?scp=84897823605&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897823605&partnerID=8YFLogxK

U2 - 10.2337/db14-er04

DO - 10.2337/db14-er04

M3 - Comment/debate

AN - SCOPUS:84897823605

SN - 0012-1797

VL - 63

SP - 1428

JO - Diabetes

JF - Diabetes

IS - 4

ER -

Flavonoid apigenin is an inhibitor of the NAD+ase CD38: Implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome (Diabetes (2013) 62 (1084-1093))

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this

Flavonoid apigenin is an inhibitor of the NAD⁺ase CD38: Implications for cellular NAD⁺ metabolism, protein acetylation, and treatment of metabolic syndrome (Diabetes (2013) 62 (1084-1093))